返回
Measuring Progress in Precision Oncology
DOI:10.1158/2159-8290.CD-23-1237.png)
摘要
En 中文
In this issue of Cancer Discovery, Suehnholz and colleagues describe their efforts to quantify the gradual yet steady progress of precision oncology by surveying the regulatory approvals of targeted cancer therapies, and thus the actionability of corresponding molecular alterations in clinical practice, over more than 20 years. Their work also suggests a relationship between the discovery of candidate therapeutic targets through comprehensive tumor profiling and molecularly guided cancer drug development.
期刊
IF:
33.3
论文数:
3.9K
被引数:
3.7W
机构
引用论文
ORAL HYDRATION IN ROTAVIRUS DIARRHŒA: A DOUBLE BLIND COMPARISON OF SUCROSE WITH GLUCOSE ELECTROLYTE SOLUTION
The Lancet
IF0
Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology多体神经病理学可提高小儿神经肿瘤学的诊断准确性
NATURE MEDICINE
IF50
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients从10,000例患者的前瞻性临床测序中揭示了转移性癌症的突变景观
NATURE MEDICINE
IF50
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer量化癌症患者临床行动能力的扩展前景
CANCER DISCOVERY
IF33.3
Machine learning for genetics-based classification and treatment response prediction in cancer of unknown primary机器学习用于未知原发性癌症的遗传学分类和治疗反应预测
NATURE MEDICINE
IF50

